| Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. | None |
| EGFR/oncogene-driven cancers evolve during the course of the disease especially during targeted treatment. | None |
| Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection. | None |
| Human papillomavirus 16 oncoprotein regulates the translocation of beta-catenin via the activation of epidermal growth factor receptor. | None |
| miR-7 acts as an antitumor miRNA in 3LL by targeting and suppressing the expression of both EGFR and RAF-1 oncogenes. | None |
| Herpes simplex virus enhances the 7,12-dimethylbenz[a]anthracene (DMBA)-induced carcinogenesis and amplification and overexpression of c-erb-B-1 proto-oncogene in hamster buccal pouch epithelium. | None |
| Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors. | None |
| The vav oncogene antagonises EGFR signalling and regulates adherens junction dynamics during Drosophila eye development. | None |
| Combinations of exonic deletions of exon 25 to 28 lead to the oncogenic activation of EGF receptor in the absence of ligand and consequent cellular transformation, indicating a significant role of C-terminal domain in modulating EGFR activation. | None |
| These findings unveil NF-kappaB activation as a critical adaptive survival mechanism engaged by EGFR oncogene inhibition and provide rationale for EGFR and NF-kappaB co-inhibition to eliminate residual disease and enhance patient responses. | None |
| EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. | None |
| PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. | None |
| Mutant EGFR enhances the oncogenic properties of MCF10A cell line, and increases sensitivity to gefitinib. | None |
| Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes. | None |
| Data show that significantly better overall survival was observed in patients with coexistence of high epidermal growth factor receptor (EGFR) expression and low p-Akt proto-oncogene protein expression. | None |
| oncogenic EGFR kinase inhibition triggers release of exosome-like extracellular vesicles and impacts phosphoprotein and DNA content | None |
| we discuss ligand-independent EGFR signal transduction by oncogenic EGFR mutants and EGFRwt, and review the interplay between EGFRwt and EGFRvIII | None |
| Epidermal growth factor receptor proto-oncogene. Structure, evolution of properties of receptor mutants. | None |
| an oncogene swap from EGFR to MET is a novel resistant mechanism to the EGFR-TKI. This novel mechanism should be considered in order to avoid futile inhibition of the original oncogene. | None |
| The tumors of never-smokers were more often poorly differentiated and more often contained oncogenic mutations particularly EGFR mutation. | None |